APUS Apimeds Pharmaceuticals US, Inc.
Price Chart
Executive Summary
APUS filed an 8-K detailing a comprehensive settlement resolving shareholder disputes and a forbearance agreement with its $11M noteholder. The company's stock remains halted on NYSE American, and it faces a June 30, 2026 deadline to regain listing compliance. Lokahi will contribute $4M in working capital and forgive $750k in advances, but the company is under intense operational and regulatory pressure.
Actionable Insight
Monitor APUS for filing of 10-K and NYSE listing application. Stock remains halted; any delays in meeting forbearance conditions could trigger default. The settlement reduces immediate governance risk but does not address fundamental liquidity or operating performance.
Key Facts
- Settlement resolves disputes among APUS, MindWave, Lokahi, and Inscobee; Inscobee grants irrevocable proxy to management.
- Lokahi to transfer $4M working capital to APUS/Newco by April 29, 2026, and forgive $750k advance.
- APUS enters forbearance with Alto Opportunity Master Fund on $11M convertible note; conditions include filing 10-K by April 30, 2026 and regaining NYSE compliance by June 30, 2026.
- Stock trading halted on NYSE American; company must obtain listing approval, effect 1-for-10 reverse stock split, and resume trading by June 30, 2026.
- Board transitions: interim board of three directors, then three new independent directors appointed by Inscobee subject to Menon's approval.
- Newco to be formed as wholly owned subsidiary, to be spun off within 12 months; 90% of net financing proceeds go to MindWave, 10% to Newco.
- Emerson files to dismiss lawsuit against Inscobee; mutual releases among parties.
Financial Impact
Lokahi contributes $4M working capital; note principal $11M; total cash inflow $4M offset by $750k forgiveness.
Risk Factors
- Failure to meet forbearance conditions could trigger note acceleration and default.
- NYSE delisting if listing application is denied or compliance not regained by June 30, 2026.
- Uncertainty over Newco spin-off and valuation.
- Potential dilution from preferred stock conversion and note conversion.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-051125 |
| Document: ea0288393-8k_apimeds.htm | 0001213900-26-051125 |
| Document: ea028839301ex10-3.htm | 0001213900-26-051125 |
| Document: ea028839301ex10-2.htm | 0001213900-26-051125 |
| Document: 0001213900-26-051125-index-headers.html | 0001213900-26-051125 |
| Document: 0001213900-26-051125-index.html | 0001213900-26-051125 |
| Document: 0001213900-26-051125.txt | 0001213900-26-051125 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 5, 2026
5w ago
|
8-K
| $3.00 $1.32 | ▼ −56.00% | ▼ −60.95% | $1.28 (−57.33%) |
|
May 4, 2026
5w ago
|
8-K
| $1.88 $1.52 | ▲ +19.15% | ▲ +24.79% | $1.28 (+31.91%) |
|
Apr 16, 2026
8w ago
|
8-K
| $1.88 $1.37 | ▲ +27.13% | ▲ +32.50% | $1.28 (+31.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access